Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16197510 | 0.86 | KDM4E (0.56) | KDM4ESIGMAR1 | |
| SCHEMBL17563432 | 0.86 | KDM4E (0.42) | KDM4ESIGMAR1HRH3 | |
| SCHEMBL16197649 | 0.86 | KDM4E (0.56) | KDM4ESIGMAR1 | |
| SCHEMBL18811761 | 0.86 | KDM4E (0.42) | KDM4ESIGMAR1HRH3 | |
| SCHEMBL27817329 | 0.86 | SIGMAR1 (0.56) | KDM4ESIGMAR1MMP2MMP9MMP8 | |
| SCHEMBL16202129 | 0.85 | KDM4E (0.41) | KDM4ESIGMAR1HRH3MMP2MMP9 | |
| SCHEMBL18522948 | 0.85 | KDM4E (0.41) | KDM4ESIGMAR1HRH3MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL16197613 | 0.84 | KDM4E (0.40) | KDM4ESIGMAR1HRH3MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL16197611 | 0.84 | KDM4E (0.40) | KDM4ESIGMAR1HRH3MMP2MMP9 | |
| SCHEMBL18811648 | 0.82 | HRH3 (0.44) | KDM4ESIGMAR1HRH3MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017072196-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-05-04 | — | — | WO | disclosed |
| WO-2016173682-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2016-11-03 | — | — | WO | disclosed |
| WO-2015162291-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-10-29 | — | — | WO | disclosed |
| WO-2014174062-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2014-10-30 | — | — | WO | disclosed |